Cantemir Alina, Alexa Anisia-Iuliana, Galan Bogdan Gabriel, Anton Nicoleta, Ciuntu Roxana Elena, Danielescu Ciprian, Chiselita Dorin, Costin Danut
Grigore T. Popa University of Medicine and Pharmacy Sanoptic Eye Center, Iasi, Romania.
Medicine (Baltimore). 2017 Nov;96(47):e8758. doi: 10.1097/MD.0000000000008758.
The purpose of this retrospective study was to report the results of iontophoretic corneal collagen crosslinking (I-CXL) with riboflavin and ultraviolet A irradiation in patients affected by keratoconus, each with thinnest pachymetry values of <400 μ (with epithelium) and not treatable using standard epithelium-off technique.Fifteen eyes of 15 patients affected by progressive keratoconus and with thinnest pachymetry values <400 μ underwent I-CXL. The uncorrected (UDVA) and corrected (CDVA) distance visual acuity, maximum and minimum keratometry (K max and K min) readings, corneal thickness at the thinnest point (CTTP), endothelial cell density (ECD), and intraocular pressure (IOP) were assessed before I-CXL, at 1, 3, 6, and 12 months postoperatively.The mean UDVA and CDVA significantly increased 12 months after I-CXL (P = .002 for both comparisons). The K max readings significantly decreased at 6 and 12 months postoperatively (P = .04 and P = .02, respectively). The mean CTTP improved at the end of the follow-up (P = .008). ECD was unchanged. No side effects or damage to the limbal region was observed during the follow-up period.I-CXL has been proved to be effective in halting keratoconus progression in eyes with very thin corneas, with no side effects during the follow-up period. This procedure could be used in patients with more advanced keratoconus.
本回顾性研究的目的是报告在圆锥角膜患者中采用核黄素和紫外线A照射进行离子导入角膜交联术(I-CXL)的结果,这些患者的最薄角膜厚度值<400μm(含上皮)且无法采用标准的去上皮技术进行治疗。15例进展期圆锥角膜患者的15只眼睛,其最薄角膜厚度值<400μm,接受了I-CXL治疗。在I-CXL术前、术后1个月、3个月、6个月和12个月时,评估未矫正远视力(UDVA)、矫正远视力(CDVA)、最大和最小角膜曲率读数(K max和K min)、最薄点处的角膜厚度(CTTP)、内皮细胞密度(ECD)和眼压(IOP)。I-CXL术后12个月时,平均UDVA和CDVA显著提高(两组比较P均=0.002)。术后6个月和12个月时,K max读数显著降低(分别为P=0.04和P=0.02)。随访结束时,平均CTTP有所改善(P=0.008)。ECD无变化。随访期间未观察到任何副作用或角膜缘区域损伤。I-CXL已被证明对阻止角膜非常薄的圆锥角膜进展有效,随访期间无副作用。该手术可用于更晚期圆锥角膜患者。